CorMedix (NASDAQ: CRMD) grants 133,156 RSUs to Chief Commercial Officer

Rhea-AI Filing Summary

CorMedix Inc.’s Chief Commercial Officer, Michael David Seckler, reported an equity compensation grant of 133,156 shares of common stock on 01/08/2026. The filing shows these as restricted stock units, each representing the right to receive one share of CorMedix common stock at a stated price of $0 per unit.

The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, and vesting requires Mr. Seckler to remain employed through each applicable vesting date. After this grant, he beneficially owns 133,156 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Seckler Michael David

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	133,156	$0.00	--

Holdings After Transaction: Common Stock — 133,156 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seckler Michael David

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A		133,156	A	$0(1)	133,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These Restricted Stock Units were granted on 01/08/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date.

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix (CRMD) report in this Form 4?

The report shows that Chief Commercial Officer Michael David Seckler received an equity grant tied to 133,156 shares of CorMedix common stock on 01/08/2026.

How many CorMedix (CRMD) shares are involved in Michael Seckler’s grant?

The transaction covers 133,156 restricted stock units, each representing the right to receive one share of CorMedix Inc. common stock.

What is the vesting schedule for Michael Seckler’s CorMedix (CRMD) restricted stock units?

The restricted stock units vest over four years in four equal installments on the first four anniversaries of the 01/08/2026 grant date, subject to continued employment.

What price per share is shown for the CorMedix (CRMD) restricted stock units granted to Michael Seckler?

The filing lists a transaction price of $0 per share, reflecting that the award is a restricted stock unit compensation grant rather than an open-market purchase.

How many CorMedix (CRMD) shares does Michael Seckler beneficially own after this transaction?

Following the reported grant, 133,156 shares are shown as beneficially owned directly by Michael David Seckler.

What is Michael Seckler’s role at CorMedix (CRMD)?

Michael David Seckler is identified as an officer of CorMedix Inc., serving as its Chief Commercial Officer.